Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management
- Written by PR Newswire
MANCHESTER, England, March 4, 2024 /PRNewswire/ -- Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing all equity investment round. The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led...
